BioPharm Videos

Edwin Stone, PhD, CEO of Cellular Origins, offers his unique perspective to the challenges facing CGT manufacturers, drawing on his background in robotics and life science automation.

Vector Bioscience Cambridge is developing highly porous nanomaterials that can help reduce toxicities due to the small amount of vehicle material.

William Oh, MD, led a panel discussion during which the practicalities of incorporating AI tools into the daily workflow of busy clinicians were discussed.

Eswar Iyer, MS, PhD, CEO and co-founder at Aikium Inc., describes a tool to overpower the data paucity problem in proteins.

Jane True, Dr Andreas Kuhn, and Dr Andy Geall discuss mRNA risks, costs, effectiveness, manufacturing logistics, public messaging, and regulatory challenges.

Jane True, Dr Andreas Kuhn, and Dr Andy Geall discuss mRNA risks, costs, effectiveness, manufacturing logistics, public messaging, and regulatory challenges.

Jane True, Dr Andreas Kuhn, and Dr Andy Geall discuss mRNA risks, costs, effectiveness, manufacturing logistics, public messaging, and regulatory challenges.

Laks Pernenkil, Brian Feth, and Alex Philippidis go behind the headlines to discuss the impact of recent news, including FDA’s drug shortage list update, Nobel prize winners in microRNA and AI, and a big-potential research win for RNA editing.

Cell and gene therapy experts Fabian Gerlinghaus, Dr. Claudia Zylberberg, and Benjamin McLeod weigh in on hot topics in CGT.

Cell and gene therapy experts Fabian Gerlinghaus, Dr. Claudia Zylberberg, and Benjamin McLeod weigh in on hot topics in CGT.

Under a pilot program initiative introduced by the Biden administration, Aaron Cowley, chief scientific officer, ReciBioPharm, talked about the ongoing progress in developing continuous manufacturing for mRNA.

In this episode of Drug Digest, industry experts discuss aseptic processing and manufacturing, including what the future holds in this area and the barriers involved with automated aseptic processing practices.

JP Bornholdt, director of modular operations, CRB, discusses continuous and modular manufacturing.

Wood CEO Ken Gilmartin gives his insight on what's currently in demand in terms of new bio/pharma manufacturing facilities.

Bas Trietsch, chief technology officer, MIMETAS, discusses the successes he's encountered so far using organ on a chip technology in bio/pharmaceutical research.

Yaakov Nahmias, founder and chief scientific officer of Tissue Dynamics, discusses the barriers in implementing organ on a chip technology.

Isaac Bentwich, MD, CEO and co-founder of Quris-AI, discusses organ on a chip technology.

James Rorke, vice-president, operations, Steriline North America, discusses the benefits of automation in fill/finish operations.

Martin Smyth, senior vice-president of Go-To-Market Strategy at MasterControl, discusses gaps in digitalization in the pharma industry.

Alessandro Zannini, sales director, engineering division, Stevanato Group, discusses artificial intelligence and digitalization in the pharma field.

Mariano Mattei, vice-president of cybersecurity and CISO for Azzur Group, goes in depth about cybersecurity in the pharma field.

Emily Moran, senior vice-president of vector manufacturing and supply chain at The Center for Breakthrough Medicines, talks about manufacturing processes for viral vectors in the cell and gene therapy space, and more.

Michael Blackton, senior vice-president of technical operations at Elektrofi, speaks about comparability in cell and gene therapy.

Phil Challis, vice-president of product development at eTheRNA, discusses four of the major challenges in working with mRNA therapeutics.

Biopharma industry faces production challenges as gene therapies move from clinical to commercialization.

Mass-produce cell and gene therapies presents the biopharma industry with a unique set of challenges.

Researchers in China are playing a role in advancing gene therapy development.